(VTVT) vTv Therapeutics Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VTVT) vTv Therapeutics Inc. Complete Analysis Pack
vTv Therapeutics’ Business Model, Simplified
Discover how vTv Therapeutics Inc. turns its biotech strategy into a clear business model. This concise Business Model Canvas highlights its value proposition, key partnerships, customer focus, and revenue logic. If you want the full strategic picture, get the complete canvas for deeper analysis and smarter decision-making.
Partnerships
HPP593 license with Reneo Pharmaceuticals
vTv Therapeutics Inc.’s HPP593 license with Reneo Pharmaceuticals covers its peroxisome proliferator-activated receptor delta (PPARδ) program and moves development and any future commercialization to an external partner. This setup lowers vTv’s need to fund 100% of the program itself, while keeping exposure to one partnered asset instead of carrying all development risk alone.
Novo Nordisk A/S diabetes collaboration
vTv Therapeutics Inc.’s Novo Nordisk A/S diabetes collaboration ties it to a global leader in diabetes care, which had DKK 290.4 billion in revenue in 2024. It supports R&D in vTv Therapeutics Inc.’s core metabolic focus and boosts credibility in a market where 589 million adults live with diabetes worldwide.
JDRF International research support
JDRF International, now Breakthrough T1D, is a key diabetes nonprofit partner for vTv Therapeutics Inc., giving TTP399 stronger credibility in Type 1 diabetes research. With about 1.6 million Americans living with Type 1 diabetes, the link helps vTv reach the patient and advocacy network that shapes trial access, awareness, and adoption.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. agreement
vTv Therapeutics Inc.’s agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. expands its external pharma network, supporting licensing and development work while widening reach in China. It also helps vTv add commercial scale beyond its core U.S. footprint.
- Broader licensing access
- Shared development support
- Added geographic reach
- Stronger commercialization path
Newsoara Biopharma Co., Ltd. collaboration
Newsoara Biopharma Co., Ltd. gives vTv Therapeutics Inc. another external partner for its pipeline, which helps spread research and development risk beyond one counterparty. It also supports regional partnering work, so vTv can push programs through more than one channel.
- Broadens pipeline support
- Supports R&D and regional deals
- Reduces single-partner dependence
This kind of tie-up matters because vTv can keep more shots on goal while sharing development burden and access to local markets. In 2025, that partner mix is a key signal of flexibility and lower concentration risk.
vTv’s Partner Network Strengthens Diabetes R&D and Reduces Risk
vTv Therapeutics Inc. relies on external partners to share R&D cost, widen reach, and lower single-asset risk. Its Novo Nordisk A/S tie and Breakthrough T1D link strengthen diabetes work, while Reneo, Huadong, and Newsoara extend licensing and regional support.
| Partner | Role | Value |
|---|---|---|
| Novo Nordisk A/S | Diabetes R&D | DKK 290.4b revenue, 2024 |
| Breakthrough T1D | Type 1 diabetes support | 1.6m U.S. patients |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for vTv Therapeutics, mapping its drug-development strategy, partnerships, customers, channels, and value creation.
Customizable Excel Spreadsheet
Quickly maps vTv Therapeutics’ pain-point reliever logic into a one-page business snapshot for fast review.
Reference Sources
Provides a credible source trail for vTv Therapeutics Inc., helping validate claims fast and support informed decisions.
Activities
TTP399 clinical development
vTv Therapeutics advances TTP399 through clinical development as its core activity: an oral, small-molecule, liver-specific glucokinase activator for Type 1 diabetes. The asset has moved into human testing, with development focused on proof of glycemic control, safety, and hypoglycemia risk, which are the key gates for any diabetes therapy.
HPP737 inflammatory disease development
vTv Therapeutics develops HPP737 as an oral PDE4 inhibitor that is designed to stay out of the blood-brain barrier, aiming at inflammatory disease and psoriasis. This key activity blends medicinal chemistry with clinical testing to refine selectivity, safety, and once-daily oral use in a crowded dermatology and immunology market.
Oral diabetes pipeline execution
vTv Therapeutics runs oral metabolic therapy work, led by TTP273, to blunt postprandial glucose spikes and other diabetes-related needs. This is a core platform activity for the Company, which is still focused on advancing oral, non-injectable options in a market where the ADA reports over 38 million Americans have diabetes.
Partnered research and licensing management
vTv Therapeutics uses partnered research and licensing management to run multiple pharma and research collaborations, and deal execution sits at the center of its nonclinical work. This lets the Company keep external science moving while it shares development rights, milestones, and economics across partners.
Manages multiple active collaborations.
Works with pharma and research groups.
Licensing drives nonclinical execution.
Regulatory and trial operations
vTv Therapeutics Inc. runs regulatory and trial operations to coordinate studies, FDA submissions, and development documents across its clinical-stage pipeline. With 0 approved products and ongoing programs in 2025, every trial must meet strict compliance rules, so execution quality directly affects each asset.
- Coordinates study operations and filings
- Maintains GCP and FDA compliance
- Supports each pipeline program
vTv Therapeutics Pushes 3 Oral Programs, with No Approved Products Yet
vTv Therapeutics Inc. centers its key activities on advancing TTP399, HPP737, and TTP273 through clinical testing, with no approved products and 2025 still focused on proof of safety, efficacy, and oral convenience. It also manages licensing and collaboration work plus FDA and trial operations, because execution quality drives every pipeline readout.
| Key activity | 2025 status |
|---|---|
| Clinical development | 3 oral programs |
| Commercial output | 0 approved products |
What You See Is What You Get
Business Model Canvas
The vTv Therapeutics Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a direct view of the real file, formatted the same way and ready to use. Once you buy, you’ll get full access to this same complete document.
Resources
Multi-asset clinical pipeline
vTv Therapeutics’ key resource is its multi-asset clinical pipeline, with 7 investigational programs it owns or controls: TTP399, HPP737, TTP273, HPP3033, azeliragon, HPP971, and HPP593-linked rights. This pipeline is the company’s main asset base and drives most of its value creation, especially as development data advance.
Oral small-molecule expertise
vTv Therapeutics Inc. builds its business around oral small-molecule chemistry, pairing disease-specific mechanism design with a platform that can be reused across multiple indications. Its lead oral asset, cadisegliatin, was in Phase 2 development in 2025, showing how this know-how turns one chemistry base into several shots on goal.
Clinical development know-how
vTv Therapeutics Inc. is a clinical-stage company, so its main resource is know-how in science, trial design, and regulation. This matters across its pipeline, including cadisegliatin, because moving a drug from lab work into human studies can take years and requires disciplined execution, data review, and FDA-ready documentation.
Licensed and partnered program rights
vTv Therapeutics Inc. treats licensed and partnered program rights as core intangible assets because they give the Company access to externally developed programs and can trigger future milestones and royalties. These rights matter most when partnerships convert pipeline progress into non-dilutive cash flow, while vTv keeps the downside of early R&D off its balance sheet.
- External agreements support pipeline access
- Milestones can add future cash inflows
- Royalties can scale with approvals
High Point, North Carolina headquarters
vTv Therapeutics Inc. is headquartered in High Point, North Carolina, and that site supports executive, research, and corporate functions. In its latest 2025 reporting, this HQ remains the hub that links program work with partners and helps keep decision-making close to the pipeline.
- High Point HQ anchors coordination.
- Supports executive and research teams.
- Connects programs with partners.
vTv’s 7-Program Pipeline Hinges on Cadisegliatin Execution
vTv Therapeutics Inc.’s key resources are its 7-program clinical pipeline, oral small-molecule know-how, and partner rights. In 2025, cadisegliatin stayed in Phase 2, so execution on trial design, FDA-ready work, and data generation remains the main value driver.
| Resource | 2025 data |
|---|---|
| Clinical pipeline | 7 investigational programs |
| Lead asset | Cadisegliatin, Phase 2 |
| Headquarters | High Point, North Carolina |
Value Propositions
Oral alternatives to injectable therapies
vTv Therapeutics Inc. centers its pipeline on oral small molecules, giving patients a needle-free option versus injectable or biologic therapies. That clear dosing edge can improve convenience, and the company remains pre-commercial, so oral use is one of its strongest patient-facing differentiators.
TTP399 for Type 1 diabetes
TTP399 (cadisegliatin) is a liver-specific glucokinase activator designed for Type 1 diabetes, aiming to improve glucose control through a differentiated, non-insulin mechanism. In vTv Therapeutics’ Phase 2 study, it lowered HbA1c by about 0.6 percentage points at 12 weeks without raising severe hypoglycemia.
HPP737 without CNS penetration
HPP737 is vTv Therapeutics Inc.’s non-CNS penetrant PDE4 inhibitor, designed to limit central nervous system exposure while targeting inflammatory disease and psoriasis. That profile fits a market where plaque psoriasis affects about 7.5 million adults in the U.S., supporting a clear need for safer anti-inflammatory options.
Broad pipeline across multiple diseases
vTv Therapeutics spreads its science across 5 disease areas: diabetes, inflammation, renal disease, lung disorders, and oncology, so one program setback does not stop the whole pipeline. That gives the company multiple shots on goal and keeps value tied to several markets, not just one lead asset.
- 5 therapeutic areas
- Broader risk spread
- Multiple clinical shots
Partnerable assets for commercialization
vTv Therapeutics Inc. builds clinical-stage assets that can be licensed or partnered, so value can be realized before any full commercial launch. That is attractive to larger pharma companies because it lowers early R&D risk and lets vTv turn pipeline progress into upfront payments, milestones, and royalties.
In 2025/2026, that model matters even more for a small-cap biotech with no broad product sales, since asset-level deals can fund development while preserving upside in programs like cadisegliatin. It is a clean way to monetize innovation before the company has to build a full sales force.
- Licensable assets reduce partner risk
- Upfront cash can fund R&D
- Milestones and royalties keep upside
- Value can arrive before launch
vTv Therapeutics: Oral Assets, Multiple Shots on Goal
vTv Therapeutics Inc. offers oral, small-molecule assets that can improve convenience and support partnering before commercialization. Its value comes from three clear edges: needle-free dosing, multiple disease shots, and asset-level licensing upside.
| Driver | Data |
|---|---|
| Therapeutic areas | 5 |
| Psoriasis market | 7.5M U.S. adults |
| Lead model | Oral small molecules |
Customer Relationships
Trial-participant relationship model
vTv Therapeutics Inc. relies on clinical trial volunteers, not retail customers, so its customer relationship is direct, protocol-driven, and centered on informed consent. In practice, this model is tied to regulated study operations under IRB oversight and FDA rules, with value creation flowing through patient enrollment and retention rather than repeat sales; vTv reported no product revenue in 2025.
Investigator-led study engagement
vTv Therapeutics Inc. relies on investigator-led study engagement with clinical investigators and trial sites to run protocols and collect trial data. These ties are central to moving assets through development, as shown by its 2025 clinical pipeline focus, where execution quality at sites can make or break readouts.
Partner-governed collaboration management
vTv Therapeutics Inc. keeps customer ties mostly B2B, working through licensing and research partners rather than end users. These relationships are governed by milestone-based development plans, shared data, and joint review points, so partner progress drives the commercial link.
Scientific and medical community communication
vTv Therapeutics Inc. uses conferences, publications, and development updates to keep the scientific and medical community informed, which supports awareness and credibility. These touchpoints help explain its mechanism of action and trial progress, especially for a clinical-stage company with a small pipeline and limited commercial revenue.
- Conferences build visibility.
- Publications support credibility.
- Updates explain mechanism and progress.
Investor and shareholder outreach
vTv Therapeutics must keep Nasdaq investors updated with timely SEC filings, trial-readout news, and financing plans. For a clinical-stage Company Name, that outreach is tied directly to capital access and dilution control; cash runway and study milestones can move the stock fast.
- SEC filings and earnings updates
- Trial data and pipeline milestones
- Capital plans and runway visibility
vTv Therapeutics: Trial-Driven Relationships, No Product Revenue
vTv Therapeutics Inc. keeps customer relationships tightly regulated and direct: trial volunteers give informed consent, while investigators and study sites run protocol-led engagement under FDA and IRB oversight. In 2025, the Company reported no product revenue, so relationship value came from enrollment, retention, and clean data.
| Channel | 2025 fact |
|---|---|
| Trial volunteers | No product revenue |
| Investigators and sites | Protocol-led execution |
| Investors | SEC filings and trial updates |
Channels
Clinical trial sites
vTv Therapeutics Inc. reaches patients through investigator sites and study centers, which are the main gate for enrollment and data capture in its clinical programs. This matters because its 2025 filings show the company remains clinical-stage, so site execution drives trial speed, data quality, and cash burn control.
Partner licensing networks
vTv Therapeutics Inc. uses pharmaceutical and research partners as licensing channels to turn R&D assets into regional or commercial deals, especially for its lead asset cadisegliatin, which is still in development. This model is central to out-licensing, since vTv has no approved products and relies on partners to move programs closer to market.
Scientific conferences
vTv Therapeutics Inc. uses scientific conferences to present clinical and preclinical data, which helps build awareness with clinicians, researchers, and potential partners. In early-stage biotech, peer visibility matters because conference posters and talks can support credibility before broad commercial sales start.
Investor relations communications
vTv Therapeutics Inc. uses SEC filings, press releases, and corporate updates to keep shareholders and analysts informed. These channels support financing by signaling trial progress, cash needs, and valuation milestones, and they are the main public path for market-moving updates.
- SEC filings for formal disclosure
- Press releases for key milestones
- Corporate updates for valuation signals
Corporate website and digital disclosures
vTv Therapeutics Inc. uses its corporate website and digital disclosures to publish pipeline updates, trial status, and collaboration news in one place. In fiscal 2025, this helped support partner and investor discovery by keeping the latest company and SEC materials easy to find online.
The channel is especially important for a clinical-stage biotechnology Company like vTv Therapeutics Inc., because trial readouts and partnership changes can move quickly and need clear, timely communication. One clean site page can carry pipeline facts, investor decks, and disclosure links without delay.
- Shares pipeline updates online
- Posts trial status changes fast
- Highlights collaboration news clearly
- Supports partner and investor discovery
vTv Therapeutics’ 2025 story: clinical sites and disclosures drive investor signal
vTv Therapeutics Inc. reaches patients through investigator sites and study centers, while SEC filings, press releases, and its website carry trial and financing updates to investors and partners. In 2025, its clinical-stage model meant these channels mattered more than product sales because cadisegliatin is still in development.
| Channel | Use | 2025 signal |
|---|---|---|
| Sites | Enroll and capture data | Clinical-stage |
| SEC/PR | Disclose milestones | No approved products |
Customer Segments
Type 1 diabetes patients
Type 1 diabetes patients are vTv Therapeutics Inc.’s core clinical customer segment for TTP399, a once-daily oral adjunct aimed at insulin-treated care. In the U.S., about 1.7 million people live with type 1 diabetes, and endocrinologists and diabetes specialists are the key prescribers shaping adoption.
Inflammatory disease and psoriasis patients
HPP737’s customer segment is patients with inflammatory disease and psoriasis who need an oral therapy that does not cross the blood-brain barrier; psoriasis affects about 7.5 million people in the U.S., and dermatology and immunology specialists drive treatment choice.
Cystic fibrosis-related diabetes patients
TTP273 targets postprandial glucose spikes in cystic fibrosis-related diabetes, a defined niche inside the roughly 31,000 people living with cystic fibrosis in the U.S.; CFRD affects about 20% of adolescents and 40% to 50% of adults with cystic fibrosis. Access often runs through specialized cystic fibrosis care centers, so adoption depends on these referral hubs.
Renal disease patients
Renal disease patients are a clear target for vTv Therapeutics Inc.’s HPP971, which is being developed for kidney uses tied to oxidative stress, a key driver in chronic kidney damage. This segment is largely treated by nephrology specialists; chronic kidney disease affects about 37 million U.S. adults, or 1 in 7, which shows the scale of the need.
- HPP971 targets oxidative stress
- Managed by nephrology specialists
- CKD affects 37M U.S. adults
Pharmaceutical development partners
vTv Therapeutics Inc. also sells to pharmaceutical development partners that want to license external assets, not build every program in-house. These buyers value early clinical de-risking and can help turn a single asset into a paid collaboration.
For vTv Therapeutics Inc., this is a core B2B segment because it matches partners that want lower R&D risk and faster access to differentiated science.
- License-ready clinical assets
- External innovation buyers
- Risk-sharing partnership model
vTv Therapeutics Targets Niche Specialist Patients and Pharma Partners
vTv Therapeutics Inc.’s customer segments are narrow, specialist-led patient groups plus pharma partners: type 1 diabetes, cystic fibrosis-related diabetes, psoriasis/inflammatory disease, and kidney disease. Adoption runs through endocrinology, dermatology, cystic fibrosis, and nephrology centers, while out-licensing buyers want de-risked, late-stage assets.
| Segment | Key need |
|---|---|
| Patients | Oral, specialist therapies |
| Partners | Licensed, de-risked assets |
Cost Structure
Clinical trial spending
In vTv Therapeutics Inc., clinical trial spending is the main cost driver: site fees, monitoring, data management, and patient costs rise fast as more programs run at once. In its latest annual filings, research and development expense was about $18 million in 2024, showing how human studies dominate the cost base.
Research and development payroll
Research and development payroll is a fixed cost base for vTv Therapeutics Inc., covering scientists, clinicians, and regulatory staff who keep programs moving and manage trial partners. In small biotech models, this spend usually sits inside the largest operating line, and it directly supports pipeline advancement, data review, and FDA-ready work.
Preclinical and manufacturing costs
In 2025, vTv Therapeutics still had to fund formulation work, GLP studies, and cGMP drug supply for its oral small-molecule pipeline, including cadisegliatin. These costs rise at each phase gate, because a program can move from discovery batches to Phase 2/3 manufacturing lots and larger clinical supply runs.
Regulatory, quality, and legal expenses
vTv Therapeutics’ regulatory, quality, and legal spend is tied to FDA submissions, trial documentation, and IP defense, so it stays recurring even when programs slow. In 2025, this cost bucket sat inside its operating spend alongside ongoing licensing and patent work, which can add thousands of dollars per filing and yearly maintenance fees.
- FDA filings and compliance
- License and contract review
- Patent protection and upkeep
General and administrative overhead
vTv Therapeutics Inc.'s general and administrative overhead is tied to public-company duties: SEC reporting, board governance, finance, investor relations, and headquarters support. For a small biotech, these fixed costs stay high even when R&D spend swings, so they can take a material share of cash use and pressure runway.
- SEC reporting and governance costs
- Finance, IR, and HQ support
- Fixed overhead hurts small biotechs
vTv Therapeutics’ R&D Spend Hits About $18 Million
vTv Therapeutics Inc.’s cost base is dominated by clinical development, with research and development expense near $18 million in 2024. That spend covers trial sites, monitoring, patient work, and the scientists and regulatory staff who keep cadisegliatin and other programs moving.
| Cost driver | Latest data |
|---|---|
| R&D expense | About $18 million, 2024 |
Revenue Streams
Upfront licensing fees
vTv Therapeutics Inc. can get cash upfront when it out-licenses a program, and those one-time fees are common in biotech partnering deals. They give the Company non-dilutive funding, so it can fund trials without issuing new shares.
Development milestone payments
Development milestone payments can lift vTv Therapeutics Inc. cash flow when a partner hits trial or FDA steps, so revenue stays tied to program progress. In biotech, these fees can be large but irregular; vTv Therapeutics Inc. reported $0.0 million collaboration revenue in 2024 and ended Q1 2025 with $55.8 million in cash and equivalents, so new milestones would matter.
Commercial milestone payments
In FY2025, vTv Therapeutics Inc. had no commercial product sales, so commercial milestone payments were still a future, back-end revenue stream. These payments usually arrive after launch or sales thresholds, and can be worth millions, but only if commercialization succeeds.
R and D reimbursement income
R and D reimbursement income lets vTv Therapeutics shift part of partnered program costs to collaborators, which trims net cash burn and stretches runway on early-stage assets. In its latest filings, this line can be tied to collaboration-based research support, a key biotech funding source when internal R and D spend is still the biggest cash use.
- Offsets partnered R and D spend
- Reduces net cash burn
- More valuable in early biotech
Future royalties on net sales
vTv Therapeutics Inc. can earn future royalties on net sales if its partnered drugs reach the market, so this stream adds upside without the cost of making or shipping the product. The income is contingent on commercial launch and sales performance, so it can be high margin but also uncertain.
- Partnered products must reach market.
- Royalties depend on net sales.
- No direct manufacturing needed.
vTv Therapeutics: No Sales, $55.8M Cash, Irregular Revenue
vTv Therapeutics Inc. has no product sales yet, so revenue still comes from out-licensing cash, development and commercial milestones, R&D reimbursements, and future royalties. That mix is highly irregular, and FY2024 collaboration revenue was $0.0 million while Q1 2025 cash and equivalents were $55.8 million.
| Metric | Value |
|---|---|
| FY2024 collaboration revenue | $0.0m |
| Q1 2025 cash | $55.8m |
| Commercial sales | None |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.